低危非肌层浸润性膀胱癌去强化监测方案的前瞻性临床评估
本研究前瞻性评估低危非肌层浸润性膀胱癌去强化监测方案,共纳入250例患者。结果显示复发率14.4%、进展率1.6%,与方案前结局相似;结论认为该方案安全,可在维持肿瘤学结局的同时减少操作与费用。
要点
- 低危膀胱癌监测第2、4年可以尿试纸血尿初筛,阳性再行膀胱镜
- 尿试纸血尿阴性预测值全程高于94%,支持其作为初筛工具
核心结论
- 去强化监测方案在低危膀胱癌中 appears safe,维持临床结局的同时减少操作与费用。
研究设计与样本
- 监测第2、4年由全科医生行尿试纸血尿检测,阳性者再行软性膀胱镜检查,数据用标准化院内表单前瞻记录。
- 统计分析使用Stata-BE version 19.0 for Mac。
主要发现
- 250例患者中复发率14.4%,进展率1.6%,与方案前结局相似。
- 尿试纸血尿的阴性预测值在整个监测期间保持在94%以上。
关键数值与推荐
- 低危膀胱癌监测第2年和第4年,仅当尿试纸血尿阳性时才进行软性膀胱镜检查。
- 尿试纸血尿阴性预测值全程高于94%。
- 复发率14.4%,进展率1.6%。
临床怎么用
- 对低危非肌层浸润性膀胱癌患者,可在监测第2、4年采用尿试纸血尿初筛替代常规膀胱镜。
- 尿试纸血尿阳性者再转诊行软性膀胱镜检查,以降低侵入性操作负担和费用。
- 实施中需由全科医生完成尿试纸检测并配合标准化记录流程。
局限性
- 缺乏随机化。
- 监测第4年和第5年队列样本量较小。
- 缺少患者报告结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recent Edinburgh-based research demonstrated high negative predictive value (NPV) for urinary dipstick testing for haematuria (UDH) in low-risk bladder cancer surveillance. This enabled a new protocol where flexible cystoscopy in surveillance years 2 and 4 is performed only if UDH is positive. Adopted across Scotland and included as aspirational in European Association of Urology guidelines, this protocol has yet to be validated in real-world settings. This study aims to evaluate the clinical outcomes of low-risk bladder cancer with the implementation of the new surveillance protocol. METHODS: The protocol began in December 2018. All patients with low-risk bladder cancer on initial transurethral resection of bladder tumour were included from January 2019 to February 2025. General practitioners conducted UDH in surveillance years 2 and 4; cystoscopy followed if positive. Patient and clinical data were prospectively recorded using a standardised institutional pro forma. This study performed the first clinical evaluation of the deintensified low-risk protocol. The study evaluated the recurrence and progression rates, NPV of UDH throughout surveillance, and number of check cystoscopies performed. The statistical analysis used Stata-BE version 19.0 for Mac. KEY FINDINGS AND LIMITATIONS: A total of 250 patients were observed with a recurrence rate of 14.4% and a progression rate of 1.6%, similar to preprotocol outcomes. The NPV of UDH remained above 94% throughout surveillance. Flexible cystoscopy use declined by 18.2%, saving at least £51 000. Limitations included a lack of randomisation, modest cohort sizes at 4 and 5 yr of surveillance, and absence of patient-reported outcomes. CONCLUSIONS AND CLINICAL IMPLICATIONS: The deintensified protocol appears safe, maintaining clinical outcomes whilst reducing procedural use and costs in low-risk bladder cancer.
引用
- Shah CP, Gray J, Lord-McKenzie T, et al. Clinical Evaluation of a Novel Deintensified Surveillance Protocol for Low-risk Non-muscle-invasive Bladder Cancer: A Prospective Study in 250 Patients. Eur Urol Oncol. 2025. PMID: 41412840. doi:10.1016/j.euo.2025.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。